Myeloproliferative Neoplasms | Specialty

The OncLive Myeloproliferative Neoplasms condition center is a comprehensive resource for clinical news and expert insights on myeloproliferative neoplasms, including myelofibrosis, polycythemia vera, and essential thrombocythemia. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in myeloproliferative neoplasms.

Optimizing the Use of Ruxolitinib for Polycythemia Vera

July 10th 2018

Ruxolitinib's Role in Treating Polycythemia Vera

July 10th 2018

Selecting Appropriate Therapy at Progression of PV

July 10th 2018

Polycythemia Vera: Controlling HCT and WBC

July 10th 2018

Determining Inadequate Control or Intolerance in PV

July 10th 2018

Polycythemia Vera: Considerations for Frontline Therapy

July 10th 2018

Polycythemia Vera: Making a Diagnosis

July 10th 2018

Suspecting Polycythemia Vera: Challenges in Diagnosis

July 10th 2018

MPNs: Differentiating Between ET, PV, and MF

July 10th 2018

An Overview of Myeloproliferative Neoplasms

July 10th 2018

Expert Details Developments in MPN Paradigm

May 1st 2018

David S. Snyder, MD, details mutations and discusses investigational treatments within the field of myeloproliferative neoplasms.

Future Direction for Polycythemia Vera

April 26th 2018

PV: Treatment With Ruxolitinib

April 26th 2018

Rationale for JAK Inhibition in PV

April 26th 2018

PV: Clinical Use of Hydroxyurea

April 26th 2018

Clinical Control of Polycythemia Vera

April 26th 2018

Initial Approach to PV Treatment

April 26th 2018

Dr. Snyder on Ruxolitinib in Patients With Myelofibrosis

April 25th 2018

David S. Snyder, MD, associate chair and professor, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, discusses the use of ruxolitinib (Jakafi) in myelofibrosis.

PV Treatment Landscape Balancing Effective Regimens With QOL Challenges

April 18th 2018

Jeanne M. Palmer, MD, discusses the current treatment landscape for patients with polycythemia vera and highlighted the impact that ruxolitinib has had on the second-line treatment setting.

JAK Signaling Remains a Promising Target in Myeloproliferative Neoplasms

April 10th 2018

Srdan Verstovsek, MD, PhD, discusses the rationale for targeting JAK signaling, new drugs under study for this pathway, and clinical challenges associated with these therapies.